Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.» Read More
Michelle Meyer, BofA Merrill Lynch, and Richard Hoey, BNY Mellon, discuss the outlook on jobs ahead of this morning's ADP report.
Avandia's U.S. patent lapsed in 2011, a year after the FDA heavily restricted its use due to ambiguity about possible increased risk of heart attack and stroke seen in a large trial called RECORD, as well as a review of dozens of other studies.
Will Obamacare prevent a majority of Americans from obtaining health care next year? Sen. John Barrasso (R-WY) discusses.
WASHINGTON, June 3- The U.S. House of Representatives approved a bill on Monday setting out how the federal government should track prescription drugs moving through the distribution chain. A Senate version would require each individual drug unit to be traceable after a phase-in period, requiring a bigger investment in technology.
"Overall, the readjudication appears to support the previous observation that in this trial, was not associated with an increased incidence of major adverse cardiovascular events," FDA staff members said in documents released by the agency on Monday.
CNBC's Jackie DeAngelis reports on drug companies making headlines out of the ASCO conference. David Risinger, Morgan Stanley, discusses the rise in melanoma treatments shown at this year's event.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
BRUSSELS, June 3- A European regulator will fine Denmark's Lundbeck and eight other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against "pay-for-delay" deals.
June 3- An experimental cancer drug from BioMarin Pharmaceutical Inc has proven to be effective in treating patients with breast or ovarian cancers caused by mutation in the BRCA gene that repairs damaged DNA, early data show. The drug, BMN673, is part of a new class known as PARP inhibitors.
Dr. Anthony Coles, Onyx Pharmaceuticals CEO & president, discusses promising results shown with liver cancer drug Nexavar, and reveals other new drugs coming to the market.
Hal Barron, Roche/Genentech chief medical officer, shares several new developments in treating cancer, including some promising results with Roche/Genentech 's Avastin.
Nearly two-thirds of Americans who currently lack health insurance don't know yet if they will purchase that coverage by the Jan. 1 deadline set by the new Affordable Care Act, a new survey revealed Monday.
Discussing whether health and human services Secretary Kathleen Sebelius broke the law, with Sen. Lamar Alexander (R-TN) and the "Kudlow Report" crew. Also, Obamacare in California will increase individual health insurance premiums by 64-146 percent.
Bristol-Myers is presenting data on its next-generation drug Nivolumab, which treats tumors, reports CNBC's Bertha Coombs.
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Gilead is taking aim at cancer, and the company is presenting early-stage data at the oncology conference on treatment for blood cancer, reports CNBC's Bertha Coombs.
CNBC's Eamon Javers reports on changes made to Social Security and Medicare. Social Security now has resources sufficient to cover benefits until 2033.
Individuals and businesses who want to keep their health care coverage still might have to cancel it if it does not meet Obamacare standards. John Goodman, National Center For Policy Analysis; Mark Hannah, Democratic political analyst; and Robert Traynham, Former Bush-Cheney senior advisor, weigh in.
LONDON/ NEW YORK, May 30- U.S. health regulators have approved two new GlaxoSmithKline drugs for treating advanced melanoma, in the latest sign that companies are having more success getting novel medicines to market.
The Affordable Care Act is making taxpayers pay more for worse benefits. Dr. Ben Carson of Johns Hopkins University, shares his recommendations for doctors to slow down or stop Obamacare.